Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity

Journal of Endocrinology

Volumn 192, Issue 1, 2007, Pages 261-267

  Liu, Shiguang ^a   Rowe, Peter S N ^a   Vierthaler, Luke ^a   Zhou, Jianping ^a   Quarles, L Darryl ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; PROTEINASE; RECOMBINANT MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; BONE MINERALIZATION; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; GENE SEQUENCE; GENOTYPE; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SEQUENCE HOMOLOGY; UPREGULATION; VITAMIN D RESISTANT RICKETS; X CHROMOSOME;

ANIMALS; BONE MARROW CELLS; CELLS, CULTURED; CYCLOPHILIN A; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR MATRIX PROTEINS; FIBROBLAST GROWTH FACTORS; GLYCOPROTEINS; HOMEOSTASIS; HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; MICE; MICE, KNOCKOUT; PHEX PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PHOSPHATES; PHOSPHOPROTEINS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STROMAL CELLS;

EID: 33947385485     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.07059     Document Type: Article

References (34)

1. ADHR Consortium 2000 Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nature Genetic 26 345-348.
2. Argiro L, Desbarats M, Glorieux FH & Ecarot B 2001 Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone. Genomics 74 342-351.
3. Bai XY, Miao D, Goltzman D & Karaplis AC 2003 The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. Journal of Biological Chemistry 278 9843-9849.
4. Bai X, Miao D, Li J, Goltzman D & Karaplis AC 2004 Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145 5269-5279.
5. Benet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ & Strom TM 2004 FGF23 is processed by proprotein convertases but not by PHEX. Bone 35 455-462.
6. Bresler D, Bruder J, Mohnike K, Fraser WD & Rowe PS 2004 Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. Journal of Endocrinology 183 R1-R9.
7. Campos M, Couture C, Hirata IY, Juliano MA, Loisel TP, Crine P, Juliano L, Boileau G & Carmona AK 2003 Human recombinant endopeptidase PHEX has a strict S1′ specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein. Biochemical Journal 373 271-279.
8. Econs MJ & Drezner MK 1994 Tumor-induced osteomalacia-unveiling a new hormone. New England Journal of Medicine 330 1679-1681.
9. Fisher LW & Fedarko NS 2003 Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connective Tissue Research 44(Suppl 1) 33-40.
10. Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, Tkalcevic GT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ et al. 2003 Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. Journal of Biological Chemistry 278 1998-2007.
11. Guo R, Rowe PS, Liu S, Simpson LG, Xiao ZS & Darryl Quarles LD 2002 Inhibition of MEPE cleavage by Phex. Biochemical and Biophysical Research Communications 297 38-45.
12. Jain A, Fedarko NS, Collins MT, Gelman R, Ankrom MA, Tayback M & Fisher LW 2004 Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density. Journal of Clinical Endocrinology and Metabolism 89 4158-4161.
13. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H & Jonsson KB 2004 Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha 1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145 3087-3094.
14. Larsson T, Davis SI, Garringer HJ, Mooney SD, Draman MS, Cullen MJ & White KE 2005 Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology 146 3883-3891.
15. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE & Quarles LD 2003 Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. Journal of Biological Chemistry 278 37419-37426.
16. Liu H, Li W, Shi S, Habelitz S, Gao C & Denbesten P 2005a MEPE is downregulated as dental pulp stem cells differentiate. Archives of Oral Biology 50 923-928.
17. Liu S, Brown TA, Zhou J, Xiao ZS, Awad H, Guilak F & Quarles LD 2005b Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. Journal of the American Society of Nephrology 16 1645-1653.
18. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M & Quarles LD 2006a Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. Journal of the American Society of Nephrology 17 1305-1315.
19. Liu S, Zhou J, Tang W, Jiang X, Rowe DW & Quarles LD 2006b Pathogenic role of FGF23 in Hyp mice. American Journal of Physiology. Endocrinology and Metabolism 291 E38-E49.
20. Murshed M, Harmey D, Millan JL, McKee MD & Karsenty G 2005 Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes and Development 19 1093-1104.
21. Petersen DN, Tkalcevic GT, Mansolf AL, Rivera-Gonzalez R & Brown TA 2000 Identification of osteoblast/osteocyte factor 45 (OF45), a bone-specific cDNA encoding an RGD-containing protein that is highly expressed in osteoblasts and osteocytes. Journal of Biological Chemistry 275 36172-36180.
22. Quarles LD 2003 Evidence for a bone-kidney axis regulating phosphate homeostasis. Journal of Clinical Investigation 112 642-646.
23. Rowe PS, Oudet CL, Francis F, Sinding C, Pannetier S, Econs MJ, Strom TM, Meitinger T, Garabedian M, David A et al. 1997 Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Human Molecular Genetics 6 539-549.
24. Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ & Oudet CL 2000 MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67 54-68.
25. Rowe PS, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK et al. 2004 MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34 303-319.
26. Rowe PS, Garrett IR, Schwarz PM, Carnes DL, Lafer EM, Mundy GR & Gutierrez GE 2005 Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone 36 33-46.
27. Rowe PS, Matsumoto N, Jo OD, Shih RN, O'Connor J, Roudier MP, Bain S, Liu S, Harrison J & Yanagawa N 2006 Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin. Bone 39 773-786.
28. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S & Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia, PNAS 98 6500-6505.
29. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K & Yamashita T 2004a Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. Journal of Clinical Investigation 113 561-568.
30. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, Fukumoto S & Yamashita T 2004b FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochemical and Biophysical Research Communications 314 409-414.
31. The HYP Consortium 1995 A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nature Genetics 11 130-136.
32. Weber TJ, Liu S, Indridason OS & Quarles LD 2003 Serum FGF23 levels in normal and disordered phosphorus homeostasis. Journal of Bone and Mineral Research 18 1227-1234.
33. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM & Econs MJ 2001 Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney International 60 2079-2086.
34. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T et al. 2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. Journal of Clinical Endocrinology and Metabolism 87 4957-4960.